Geelonghui, August 28th - Xiduo Pharmaceuticals (301130.SZ) announced its semi-annual report for 2024, with operating income of 0.129 billion yuan, a year-on-year increase of 13.04%; net income attributable to shareholders of the listed company was 24.4517 million yuan, a year-on-year decrease of 19.36%; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 20.8314 million yuan, a year-on-year increase of 39.10%; basic earnings per share was 0.3026 yuan.
西点药业(301130.SZ)：上半年净利润2445.17万元 同比下降19.36%
West Point Pharmaceuticals (301130.SZ): The net income for the first half of the year was 24.4517 million yuan, a year-on-year decrease of 19.36%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.